key: cord-0291657-5v6a88k0
authors: Gauthier, N. P. G.; Nelson, C.; Bonsall, M. B.; Locher, K.; Charles, M.; MacDonald, C.; Krajden, M.; Chorlton, S. D.; Manges, A. R.
title: Nanopore Metagenomic Sequencing for Detection and Characterization of SARS-CoV-2 in Clinical Samples
date: 2021-08-23
journal: nan
DOI: 10.1101/2021.08.13.21261922
sha: db253a3ad8cf50dfcf6f7615ad81744840358e75
doc_id: 291657
cord_uid: 5v6a88k0

The COVID-19 pandemic has underscored the need for rapid novel diagnostic strategies to detect and characterize pathogens from clinical specimens. The MinION sequencing device allows for rapid, cost-effective, high-throughput sequencing; useful features for translation to clinical laboratory settings. Metagenomic Next-Generation Sequencing (mNGS) approaches provide the opportunity to examine the entire genomic material of a sample; allowing for detection of emerging and clinically relevant pathogens that may be missed in targeted assays. Here we present a pilot study on the performance of Sequence-Independent Single Primer Amplification (SISPA) to amplify RNA randomly for the detection and characterization of SARS-CoV-2. We designed a classifier that corrects for barcode crosstalk between specimens. Our assay yielded 100% specificity overall and 95.2% sensitivity for specimens with a RT-qPCR cycle threshold value less than 30. We assembled 10 complete (>95% coverage at 20x depth), and one near-complete (>80% coverage at 20x depth) genomes from 20 specimens that were classified as positive by mNGS. We characterized these genomes through phylogenetic analysis and found that 10/11 specimens from British Columbia had a closest relative to another British Columbian specimen. Of five samples that we had both assembled genomes, as well as Variant of Concern (VOC) PCR results, we found 100% concordance between these results. Additionally, our assay was able to distinguish between the Alpha and Gamma variants, which was not possible with our VOC PCR technique. This study supports future work examining the broader feasibility of SISPA as a diagnostic strategy for the detection and characterization of viral pathogens.

coronavirus 2 (SARS-CoV-2); a positive-sense RNA virus from the family Coronaviridae (1,2). The 53 current standard for the diagnosis of many viral infections, including SARS-CoV-2, is based on real-time 54 qualitative reverse transcription polymerase chain reaction (RT-PCR) assays (3). Due to its low cost, 55 reliability, and ability to diagnose infection known pathogens, RT-PCR has been at the forefront of viral 56 diagnostics before and during the COVID-19 pandemic (4). However, this method still requires many 57 hours of hands-on time by skilled laboratory technicians and is limited in that it only detects a 58 predetermined number of pathogens that its primers are designed to identify; unknown or unexpected 59 infectious agents will be missed (5). This is a strong rationale for exploring alternative diagnostic 60 strategies that can detect known and novel pathogens. 61 62 Metagenomic next generation sequencing (mNGS) allows all genetic material recovered directly from a 63 sample to be sequenced and analyzed in a culture-free manner. Sequence-independent single primer 64 amplification (SISPA) (6) is one such mNGS approach. SISPA enables non-selective reverse transcription 65 of all extracted RNA in a sample into cDNA and amplifies the reverse transcribed cDNA using random 66 nonamers tagged to a known primer sequence. This method has been successfully used to detect and 67 assemble genomes of avian RNA viruses (7), canine distemper virus (8), human enterovirus (9), 68 chikungunya virus, Ebola virus, hepatitis C virus (10), influenza virus (11), as well as SARS-CoV-2 for a 69 small number of samples (12, 13) . Therefore, there is a strong justification for using this approach to 70 enable detection of pathogenic agents in diagnostic laboratories. 71 72 SISPA and mNGS have several clear advantages over targeted molecular approaches. mNGS enables 73 detection of multiple pathogens and co-infection in a clinical sample, as well as potentially providing 74 information on antimicrobial resistance, virulence, and microbiota-associated dysbiosis at a particular 75 body site (14, 15) . Despite the potential advantages of this approach for clinical applications, mNGS 76 techniques have not yet been widely adopted due to their high-cost, time-intensive sample preparation, 77 limited access to sequencing infrastructure and lack of robust, easy-to-use and interpret bioinformatics 78 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Nanopore mNGS across a range of Ct values (Supplementary Figure 1) . 132

Prior to extraction, samples were vortexed and 200 uL of each sample was centrifuged at 16,000g for 3 135 minutes to pellet host cells. 140 uL of supernatant was aspirated and viral RNA was extracted from the 136 supernatant using the QIAmp Viral RNA kit (Qiagen) as previously described (11), and eluted in 30 uL 137 nuclease-free water. Samples were treated with TURBO DNase (Thermo Fisher Scientific) and incubated 138 at 37℃ for 30 minutes, followed by concentration and clean-up with the RNA Clean & Concentrator-5 kit 139 (Zymo Research); finally, eluting in 8 uL nuclease-free water. 140 141 SISPA Amplification: 142 SISPA amplification was performed as described previously (9-13). Briefly, concentrated RNA was 143 incubated with primer A (100pmol/uL; 5' -GTTTCCCACTGGAGGATA(N9) -3') and then reverse 144 transcribed using SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific). Second strand 145 synthesis was performed using Sequenase Version 2.0 (Thermo Fisher Scientific), following which, 146

RNase H was performed to digest any remaining RNA. Random amplification was performed on each 147 using AccuTaq LA DNA polymerase (Thermo Fisher Scientific) and SISPA primer B (5' -148 GTTTCCCACTGGAGGATA -3'). This reaction underwent PCR using the following conditions: initial 149 denaturation for 30 seconds at 98℃, followed by 30 cycles of 94℃ for 15 seconds, 50℃ for 20 seconds, 150 and 68℃ for 2 minutes. A final elongation step of 68°C for 10 minutes was added, prior to a final hold at 151 4℃. Amplified cDNA was purified using a 1:1 ratio of PCR Clean DX beads (Aline Biosciences) and 152 eluted in 50 uL nuclease-free water. Amplified cDNA was quantified using a Qubit 4 Fluorometer 153 (Thermo Fisher Scientific) and fragment lengths were assessed using the TapeStation 2200 automated 154 electrophoresis platform (Agilent). 155 156 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Library preparation was performed using ONT's ligation sequencing kit (SQK-LSK109 or SQK-158 LSK110). Multiplexing was performed using the native barcoding expansion 96 kit (EXP-NBD196). 159

Library preparation was performed according to the manufacturer's instructions, with several key 160 modifications. DNA repair and end-prep was performed with 1000 fmol of input cDNA and the 161 incubation times were increased to 30 minutes at 20°C, followed by 30 minutes at 65°C. Raw fast5 files were basecalled using Guppy (Version 5.0.7, Oxford Nanopore Technologies) using the --172 device cuda:0 flag to enable GPU basecalling. Output fastq files were uploaded to BugSeq (version 1.1, 173 database version: RefSeq on Jan 28, 2021) for metagenomic classification (22), and results classification 174 results were visualized in Recentrifuge (23). A representative html file containing an example 175 visualization output can be found in the supplemental material (Supplementary Data). In brief, reads were 176 demultiplexed with qcat using default run parameters (enforcing barcodes on both ends, which we have 177 defined as stringent demultiplexing), followed by quality control with prinseq-lite. Reads shorter than 178 100bp or those deemed low quality (DUST score less than 7) were discarded. Reads were then classified 179 against all of the microbial genomes in RefSeq, as well as the human genome and a library of common 180 contaminants (see 22 for details). Reads classified as SARS-CoV-2 were extracted and used to build a 181 consensus sequence with Medaka. Bases with less than 20X coverage were masked in accordance with 182 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Management/Documents/APHL-SARS-CoV-2-Sequencing.pdf). SARS-CoV-2 lineages were assessed 184 using Pangolin (Version 3.1.5, github.com/cov-lineages/pangolin), and phylogenetic analysis was 185 performed with UShER (24) (Database: GISAID, GenBank, COG-UK and CNCB [2021-07-11]) . 186

Phylogenetic trees were constructed using augur (25), rooted at the SARS-CoV-2 reference sequence, and 187 visualized in iTOL (26). Antimicrobial resistance genes were detected by aligning reads against the 188

Resfinder database (27) Amplified cDNA from a total of 43 patient swabs were sequenced on MinION sequencing devices. Of 207 these samples, 38 were either positive or had indeterminate results based on SARS-CoV-2 RT-PCR and 5 208 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint samples had negative RT-PCR results. The 38 positive and indeterminate samples had a mean Ct value of 209 27.6 and ranged from 14.7-38.7 (Supplementary Figure 1) . Sample collection dates, sample type, total 210 read counts, as well as dual barcode reads, percent human reads, and SARS-CoV-2 reads per million 211 reads sequenced (RPM) are present in Table 1 We evaluated the test performance of our mNGS assay for detecting SARS-CoV-2. A sample was 218 considered positive if one or more reads were assigned to SARS-CoV-2. Across all clinical samples, we 219 detect SARS-CoV-2 with 78.4% (95%CI 62.8%-88.6%) sensitivity and 100% specificity (95%CI 56.6%-220 100%) ( Table 2) . Previous literature has demonstrated decreased sensitivity of mNGS assays above Ct 30 221 for other viruses (11, 30) . To assess the dependence of the mNGS assay on Ct value, we performed a 222 subgroup analysis on samples above and below SARS-CoV-2 Ct 30. For samples with SARS-CoV-2 Ct < 223 30, sensitivity was 100% (95%CI 84.5%-100%), while for samples with SARS-CoV-2 Ct greater than 30, 224 sensitivity was 50% (95%CI 27.8%-72.0%). 225

We note that two of 11 negative control samples had a single read assigned to SARS-CoV-2. We 227 investigated these reads (further denoted as read one and two) to identify reasons for false positivity. Both 228 reads had the expected barcode on both ends of the read as identified by BLAST. The first read exhibited 229 100% identity over the 24 nucleotide barcode on both ends, and the second read had 100% and 83% 230 identity over the 24 nucleotide barcode on both ends. We next search these reads against the NCBI 231 nucleotide database using megaBLAST to assess whether a BugSeq classification error occurred. 232

However, both reads had top hits that exclusively matched SARS-CoV-2 with greater than 95% identity 233 over more than 90% of their total length (923 and 1752 bases, respectively). SARS-CoV-2 was detected, 234 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint despite strict dual barcode demultiplexing and removal reads with improper barcode insertions. Previous 235 studies have identified barcode crosstalk, ranging from 0.2% to 0.3% of total classified reads, on 236 Nanopore MinION flowcell results (31,32). When we examined the total SARS-CoV-2 read counts for a 237

given flowcell on flowcells with false positive negative controls, we saw that one of those flowcells has 238 the highest total SARS-CoV-2 read count of all flowcells in this study, therefore, we would expect higher 239 levels of barcode crosstalk for that flowcell (Supplementary Figure 2) . 240

We adjusted for barcode crosstalk by controlling for the total number of dual-barcoded SARS-CoV-2 242 reads on each flowcell. If we assume 0.2% of reads have incorrect barcodes ligated on both ends, and that 243 these misclassified reads are evenly distributed across all barcodes on the flowcell, we can subtract the 244 estimated number of misclassified reads from each sample. This correction yielded an acceptable 245 threshold for classifying specimens as positive or negative. After adjusting for barcode crosstalk in this 246 manner, we find that seven samples and two negative controls with SARS-CoV-2 reads detected would be 247 re-classified as negative, and all negative controls are therefore classified correctly. The overall sensitivity 248 and specificity on clinical samples after adjusting for barcode crosstalk are estimated to be 59.5% (95%CI 249 43.5%-73.7%) and 100% (56.6%-100%), respectively. Grouping by Ct value, the sensitivity estimates are 250 95.2% (95%CI 77.3%-99.2%) and 12.5% (95%CI 3.5%-36.0%%) for samples below and above Ct 30, 251 respectively (Table 3) . 252

We assessed the relationship between SARS-CoV-2 RT-PCR Ct value and SARS-CoV-2 RPM for dual 255 barcode reads, using stringent demultiplexing analysis parameters. SARS-CoV-2 log-RPM showed a 256 strong linear association with RT-qPCR Ct value (R 2 = 0.71), with lower Ct values having a higher RPM 257 on average ( Figure 1 ). This relationship did not differ by RT-qPCR gene target (E-gene, ORF1ab, or 258

RdRp) (Supplementary Figure 3) . SARS-CoV-2 genome coverage depth showed a similar relationship, 259 with decreasing coverage depth across the entire genome being associated with increasing Ct value 260 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint ( Figure 2 , Table 4 ). We produced logistic regression models to assess the probability of attaining greater 261 than 95% genome coverage at 1X, 20X, or 50X depth of coverage. We found that for every one unit 262 increase in Ct value, the odds of recovering a 95% complete genome were 0.765 (95% CI: 0.519, 0.961), 263 0.263 (95% CI: 0.023, 0.666), or 0.263 (95% CI 0.023, 0.666) on average for coverage depths of 1X, 264 20X, or 50X, respectively ( Figure 3) . Interestingly, we did not see any difference in the likelihood of 265 obtaining 95% coverage for 20X or 50X, despite slight differences in coverage depth for both of these 266 thresholds (Table 4 ; Figure 3 ). 267 268 SARS-CoV-2 metagenomic reads were used to reconstruct viral genomes. We produced ten complete 269 (greater than 95% unambiguous bases) and one near-complete consensus genome sequence (greater than 270 80% unambiguous bases) from our 20 SISPA-positive clinical specimens, masking any bases with less 271 than 20X coverage. Two partial viral genomes were constructed with 20-25% unambiguous bases. 272

Pangolin lineage assignment was successful to all complete or near complete genomes; of these five 273 underwent SARS-CoV-2 VOC PCR testing. All five whole or partial viral genomes were classified as 274 SARS-CoV-2 lineages concordant with PCR results (Table 5) . We also detected an additional VOC in a 275 sample that did not undergo VOC PCR testing. We also assessed our complete or near-complete 276 genomes in the context of global SARS-CoV-2 transmission by placing them in a phylogenetic tree 277 containing over two million publicly available SARS-CoV-2 genomes. The ten complete genomes could 278 be placed in the global phylogeny with high confidence (only one maximally parsimonious placement), 279 and the near-complete genome could be placed with lower confidence (nine maximally parsimonious 280 placements). For ten of 11 genomes derived from metagenomic data, the nearest neighbor in this tree was 281 a genome derived from the same province of sample collection, British Columbia. Additionally, for 9/11 282 study genomes, 80% or more of the nearest 50 genomes were derived from British Columbia; for the 283 remaining two study genomes, 90% or more of the nearest 50 genomes were derived from Canada ( Figure  284 4; Supplementary Figure 4 ). The UK samples did not yield well covered genomes. Subtrees with nearest 285 neighbors for all study samples are available in the supplementary material (Supplementary Figure 4) . 286

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint

We searched the BugSeq metagenomic output of our clinical specimens for alternative respiratory viruses 289 or viral or bacterial co-infections.We did not identify any other pathogenic viruses or atypical bacteria 290 such as Chlamydia pneumoniae or Mycoplasma pneumoniae. We did identify several members of the 291 normal nasopharyngeal microbiota, which when found in the lower respiratory tract, may cause disease; 292 Table 3 ). These results are consistent with other metagenomic sequencing 296 results from the nasopharynx (30). We searched our data for genes conferring antimicrobial resistance, 297 and identified 10 genes across 6 samples. We found two beta-lactamases in our dataset: blaTEM-234, a 298 class A beta-lactamase which has undetermined spectrum and derived from Escherichia coli in sample 299 P22, as well as blaOXA-85, which confers resistance to amoxicillin and amoxicillin-clavulanate, that 300 derived from Fusobacterium psuedoperiodonticum (P9). 301 302

Here, we present a robust analysis detailing the performance of SISPA coupled with Nanopore mNGS to 304 detect and characterize SARS-CoV-2 from clinical samples. Clinical specimens exhibiting a Ct < 30 305 performed well. However, test performance declined in specimens exhibiting a Ct ≥ 30 from 96.3% 306 sensitivity for samples below Ct 30 to 12.5% for samples above this cycle threshold. We found an 307 exponentially declining relationship between RPM and Ct value, such that the instantaneous change in 308 read performance was fixed as illustrated in the linear relationship between Log(RPM) and Ct value 309 ( Figure 1 ). This finding is consistent with other reports on the use of SISPA and Nanopore mNGS for 310 respiratory infections (11,33). However, our results are not consistent with SISPA and mNGS results 311 from blood and serum viral diagnostics, where Ct value did not drastically impact genome coverage (34). 312 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint abundance of host nucleic acid in different sample types. 314

Despite limitations in SISPA and Nanopore metagenomic sequencing sensitivity, this approach remains a 316 valuable technique for the detection of pathogens that are novel, unexpected or uncharacterized, and 317 therefore unsuitable for targeted approaches such as RT-qPCR or emerging CRISPR-Cas-based 318 diagnostics, which focus only on known pathogens (35). Unlike these existing diagnostic methods, 319

Nanopore mNGS can theoretically detect any pathogen and co-infections, characterize changes in the site-320 specific microbiota, and capture the carriage of critical virulence or antibiotic-resistant organisms or 321 genes, all of which can impact patient outcomes. Our approach identified several organisms in the 322 nasopharyngeal microbiota that may cause disease in the lower respiratory tract, consistent with 323 sequencing results from a recent study (30). We also did not detect any viral or atypical bacterial co-324 Table 3) , concordant with previous reports of a low prevalence of respiratory 325 co-infection in COVID-19 positive samples (36) (37) (38) . In support of this finding, our study regions saw a 326 dramatic reduction in incidence of other respiratory viruses (eg., influenza and RSV) and bacterial 327 pathogens over our collection period, thought to be secondary to public health interventions. 328

We additionally assessed the ability of SISPA-based mNGS to classify and assemble complete or partial 330 SARS-CoV-2 genomes from RT-qPCR positive specimens. This method can perform dual diagnostic and 331 molecular epidemiology functions. Reliably, we were able to assemble near-complete genomes 332 (minimum 20X coverage) up to Ct 25, underscoring the ability of this approach not only to detect 333 emerging pathogens, but also to characterize them without a priori knowledge of a pathogen's genome 334

sequence. This ability contrasts to amplicon-based sequencing methods, which require the viral sequence 335 to develop primers (39). We performed lineage typing on metagenomic-derived SARS-CoV-2 genomes 336 and found perfect concordance with VOC PCR on a small subset of our samples. Moreover, with the 337 complete and partial genomes we were able to distinguish the P.1 variant from the B.1.351 variant, which 338 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint the PCR assay was unable to do, as both variants contain the E484K and N501Y mutations in their spike 339 genes targeted by the PCR assay. Our reconstructed viral genomes were further validated through 340 phylogenetic analyses, where 10/11 samples that were of British Columbian origin were most closely 341 related to another British Columbia genome sequence. This highlights the potential of mNGS sequencing 342

to be an all-in-one assay which detects and characterizes pathogens of interest in near real-time, providing 343 critical information for clinical care, infection prevention and control and public health interventions . 344

This study examined the methodological feasibility and validity of Nanopore mNGS. We observed false 346 positive SARS-CoV-2 reads in our negative control samples despite meticulous laboratory preparation, 347

including performing nucleic acid extractions in a biological safety cabinet, using freshly aliquoted 348 reagents, decontamination of all surfaces with ethanol and RNaseZap (Thermo Fisher Scientific), and 349

performing pre-amplification steps in a dedicated PCR area. After investigating these reads, we attribute 350 them to barcode crosstalk, in accordance with previous studies (30,31). While BugSeq implements 351 methods to minimize barcode crosstalk from Nanopore sequencing, including requiring barcodes to be 352 present at both ends of each read and removal of reads with barcodes integrated elsewhere, we developed 353 a method to adjust the total read counts on a flowcell for barcode crosstalk. These enhancements 354 improved assay specificity; however, sensitivity is negatively impacted by this read count adjustment. 355

Interestingly, using the estimated 0.2% expected crosstalk between barcodes based on existing reports in 356 the literature, we find far fewer false positive reads in our negative controls than would be expected (1 357 read found in each versus 3 and 107 reads expected). We do note that native barcoding on the Nanopore 358 platform is not fully optimized, leading to a significant portion of reads with only a single barcode in our 359 sequencing datasets. This results in a decreased sensitivity, when requiring that barcodes be present on 360 both read ends. Future advances in sequencing chemistry may reduce the prevalence of barcode crosstalk 361 while preserving assay sensitivity. 362 363 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint mNGS, we validated the BugSeq as a potentially powerful clinical bioinformatics platform and workflow, 365 including quality control, data visualization, taxonomic classification, consensus sequence generation, 366 data aggregation, and results reporting. Although a lack of straight-forward and user-friendly 367 bioinformatics pipelines has long been a deterrent for clinical laboratories implementing NGS and mNGS 368 methods, our use of BugSeq as a rapid and robust bioinformatics tool has demonstrated the utility of user-369 friendly platforms for clinical diagnostics and public health service. Indeed, other groups adopting 370

MinION sequencers in clinical microbiology laboratories have reached similar conclusions (40,41). 371

Our pilot study has several limitations. Despite the MinION sequencing device providing high-throughput 373 sequencing data in real-time, this protocol is still significantly more time intensive than RT-PCR as a 374 diagnostic method, requiring a minimum of 12 hours from sample collection to prepared library, and 375

another 72 hours of sequencing to reach maximal pathogen detection sensitivity (although results could be 376 available in as little as 1-2 hours for high viral load samples). The use of liquid handling robots for 377 automated sample extraction, nucleic acid amplification, and library preparation may aid in 378 standardization. Additionally, examining the feasibility of a less time intensive library preparation 379 protocol such as the Rapid Barcoding Kit (Oxford Nanopore Technologies) for this approach will aid in 380 the optimization and translation of Nanopore mNGS for routine clinical use. The SISPA approach is also 381 limited in that it performs random amplification of both host and microbial nucleic acids. The high 382 percentage of host RNA in nasopharyngeal/oropharyngeal swabs limits our ability to rapidly detect 383 viruses with comparable sensitivity to PCR, requiring deeper sequencing than what is currently feasible 384 on a MinION. Therefore, this sequencing strategy may not be optimal for samples expected to have very 385 few viral or bacterial nucleic acids where sensitivity is paramount. We note that while assay sensitivity 386 has played an important role in public discourse surrounding SARS-CoV-2 testing, there is some data to 387

suggest that lower viral loads cannot be cultured and are less likely to be transmissible 388 (https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-amp-statement.pdf). This issue 389 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is further complicated by the difficulty of employing host nucleic acid removal techniques on low-390 biomass samples. Interestingly, the detection of host nucleic acids via mNGS may be useful, as samples 391 with lower host nucleic acid content have been shown to be associated with higher rates of false-negative 392 COVID-19 RT-PCR tests, presumably due to sample quality (42). Regardless, methods to enrich for 393 pathogen sequences or deplete host DNA to increase sensitivity have been examined (43-45), and may 394 prove useful for future clinical metagenomics studies. 395

Our pilot study represents the first analysis of performance and feasibility of SISPA-based Nanopore 397 mNGS for the detection and characterization of SARS-CoV-2. We were able to successfully detect 398 SARS-CoV-2 with 100% specificity and near perfect sensitivity for samples below Ct 30 when adjusting 399 for barcode crossover. We were also able to assemble SARS-CoV-2 genomes and characterize viral 400 lineages reliably in 10/13 of samples below Ct 25. This assay has the ability not only to detect known 401 pathogens and co-infections, but can also detect emerging pathogens, assess microbiota states, and 402 capture resistance and virulence genes. This approach holds promise as a tool for clinical diagnostics and 403 public health surveillance. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Pizzurro F, Cirone F, Zaccaria G, Cammà C, Lorusso A. 2019. Diagnosis and characterization of 440 canine distemper virus through sequencing by MinION nanopore technology. Sci Rep 9:1-9. 

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261922 doi: medRxiv preprint CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Clinical metagenomics

Highlighting Clinical Metagenomics for 465

Enhanced Diagnostic Decision-making : A Step Towards Wider Implementation

Ultrafast Sample placement on Existing tRees (UShER) enables real-time 489 phylogenetics for the SARS-CoV-2 pandemic

NextStrain: Real-time tracking of pathogen evolution

Interactive tree of life (iTOL) v3: an online tool for the display and 493 annotation of phylogenetic and other trees

ResFinder 4.0 for predictions of phenotypes from 499 genotypes

RStudio: Integrated Development for

Minimap2: Pairwise alignment for nucleotide sequences

Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: 506 diagnosis, drug resistance and nosocomial transmission

Next